Johnson & Johnson Q2 Preview: Focus on tariff threat, MedTech softness
Sundry Photography Johnson & Johnson (NYSE:JNJ) is set to kick off the second quarter pharma
Sundry Photography Johnson & Johnson (NYSE:JNJ) is set to kick off the second quarter pharma
CatLane/E+ via Getty Images A U.S. appeals court has sided with Johnson & Johnson (NYSE:JNJ)
Ekaterina79/iStock via Getty Images Johnson & Johnson (NYSE:JNJ) said on Tuesday that it is seeking
MarioGuti/iStock via Getty Images A U.S. federal judge has put a stop to the Trump
hapabapa/iStock Editorial via Getty Images Bristol Myers Squibb (NYSE:BMY) announced that the U.S. FDA has
Solskin Johnson & Johnson (NYSE:JNJ) on Monday reported new findings from an indirect treatment comparison
Incyte (NASDAQ:INCY) announced Wednesday that the U.S. Food and Drug Administration (FDA) approved a label
While access to capital funding remains elusive for many biotechs and the macroeconomic environment remains
Big Pharma sees Chinese pharma and biotech companies as increasingly attractive to do deals with
Chip Somodevilla/Getty Images News Major global pharmaceutical companies traded lower in the premarket on Tuesday